A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine.

Federica MartoranaGiuseppina ScandurraMaria Rosaria ValerioSalvatore CufariPaolo VigneriMaria Vita SanòGiuseppe ScibiliaPaolo ScolloVittorio Gebbia

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

Single-agent oral cyclophosphamide in EOC holds promise as a treatment option, even in the era of precision medicine. Genetic factors, such as DNA repair gene polymorphisms, may influence treatment response. Combining cyclophosphamide with biological agents such as PARP inhibitors or immunotherapy agents is an area of active investigation.

Keyphrases

dna repair
dna damage
high dose
low dose
dna damage response
genome wide
gene expression
big data
oxidative stress
machine learning
dna methylation
replacement therapy
deep learning